Literature DB >> 3172640

Cyclosporine A enhances vasopressin-induced Ca2+ mobilization and contraction in mesangial cells.

H Meyer-Lehnert1, R W Schrier.   

Abstract

A major problem in cyclosporine A (CsA) therapy is its nephrotoxicity, characterized by a marked fall in glomerular filtration rate (GFR). Since the glomerular ultrafiltration area is an important determinant of GFR and has been proposed to be regulated by mesangial (MS) cell contraction, we examined the effect of CsA on arginine vasopressin (AVP)-induced Ca2+ mobilization and contraction in cultured MS cells. Intracellular Ca2+, [Ca2+]i, concentrations were measured using quin 2. Basal levels were not affected by CsA (151.1 +/- 6.2 vs. 145.2 +/- 5.8 nM, NS), but 10 micrograms/ml CsA significantly augmented the 10(-8) M AVP-induced increase of [Ca2+]i (delta 94.5 +/- 6.6 vs delta 167.3 +/- 8.4 nM, P less than 0.01). This effect was also seen in Ca2+-free medium (P less than 0.01). The effect of CsA on [Ca2+]i was not due to an inhibition of 45Ca2+ efflux, since AVP-induced increase of 45Ca2+ efflux at 30 seconds was enhanced in cells pretreated with CsA (1630 +/- 185 vs. 3646 +/- 197 cpm/mg prot/30 sec, P less than 0.01). As compared to control, CsA increased 45Ca2+ uptake in MS cells (7924 +/- 414 vs. 11928 +/- 760 cpm/mg prot/5 min, P less than 0.05); this effect was not affected by the Ca2+ channel blocker verapamil (5 X 10(-5) M, P less than 0.05). MS cell contraction was evaluated by a digital imaging analysis system.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3172640     DOI: 10.1038/ki.1988.149

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

1.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents.

Authors:  M Potier; B L'Azou; J Cambar
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

3.  Cyclosporin reduces renal blood flow through vasoconstriction of arcuate arteries in the hydronephrotic rat model.

Authors:  L B Zimmerhackl; M Fretschner; M Steinhausen
Journal:  Klin Wochenschr       Date:  1990-02-01

4.  Theophylline: a new concept of nephroprotection in acute cyclosporin A nephrotoxicity?

Authors:  P M Rob; J Fandrey; W Jelkmann
Journal:  Klin Wochenschr       Date:  1989-06-15

5.  Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.

Authors:  K I Blankenstein; A Borschewski; R Labes; A Paliege; C Boldt; J A McCormick; D H Ellison; M Bader; S Bachmann; K Mutig
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-21

6.  Low density lipoprotein enhances the cellular action of arginine vasopressin in rat glomerular mesangial cells in culture.

Authors:  S Ishikawa; M Kawasumi; K Okada; T Saito
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Cyclosporin therapy in vivo attenuates the response to vasodilators in the isolated perfused kidney of the rabbit.

Authors:  H S Cairns; L D Fairbanks; J Westwick; G H Neild
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

8.  Effects of a selective adenosine A1 receptor antagonist on the development of cyclosporin nephrotoxicity.

Authors:  V S Balakrishnan; C J von Ruhland; D F Griffiths; G A Coles; J D Williams
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 9.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; S Drechsler; H J Kramer
Journal:  Clin Investig       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.